Immunotherapy for lung cancer: Has it finally arrived?

Frontiers in Oncology

Volumn 4, Issue OCT, 2014, Pages

  Mostafa, Ahmed A ^a   Morris, Don G ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Clinical trials; Immune checkpoint inhibitors; Lung cancer; Vaccines

Indexed keywords

BELAGENPUMATUCEL L; CANCER VACCINE; CARBOPLATIN; CISPLATIN; CXCL9 CHEMOKINE; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETOPOSIDE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GEMCITABINE; INTERLEUKIN 2; IPILIMUMAB; MELANOMA ANTIGEN 3; MONOCYTE CHEMOTACTIC PROTEIN 1; NAVELBINE; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TECEMOTIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN;

ADJUVANT THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; CELLULAR IMMUNITY; DRUG SAFETY; DRUG TOLERABILITY; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LOW DRUG DOSE; LUNG CANCER; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; SMALL CELL LUNG CANCER; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84907815047     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00288     Document Type: Article

References (51)

1. World Health Organization,;1; Cancer 2013 Available from: http://www.who.int/mediacentre/factsheets/fs297/en/. Cancer. 2013. 10-30-2013.
2. Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N, et al.;1; Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006 May;52(2):155-63.
3. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA.;1; Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008 May;83(5):584-94.
4. Katzel JA, Fanucchi MP, Li Z.;1; Recent advances of novel targeted therapy in non-small cell lung cancer. J Hematol Oncol 2009;2:2.
5. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, et al.;1; Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011 Oct;12(11):1004-12.
6. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al.;1; Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009 Sep 3;361(10):958-67.
7. Hanahan D, Weinberg RA.;1; Hallmarks of cancer: the next generation. Cell 2011 Mar 4;144(5):646-74.
8. Dougan M, Dranoff G.;1; The immune response to tumors. Curr Protoc Immunol 2009 Apr;Chapter 20:Unit.
9. Dougan M, Dranoff G.;1; Immune therapy for cancer. Annu Rev Immunol 2009;27:83-117.
10. Kemmler CB, Clambey ET, Kedl RM, Slansky JE.;1; Elevated tumor-associated antigen expression suppresses variant peptide vaccine responses. J Immunol 2011 Nov 1;187(9):4431-9.
11. Drake CG, Lipson EJ, Brahmer JR.;1; Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2014 Jan;11(1):24-37.
12. Nemunaitis J, Murray N.;1; Immune-modulating vaccines in non-small cell lung cancer. J Thorac Oncol 2006 Sep;1(7):756-61.
13. Akhurst RJ, Derynck R.;1; TGF-beta signaling in cancer--a double-edged sword. Trends Cell Biol 2001 Nov;11(11):S44-S51.
14. Anscher MS, Kong FM, Andrews K, Clough R, Marks LB, Bentel G, et al.;1; Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 1998 Jul 15;41(5):1029-35.
15. Rochlitz C, Dreno B, Jantscheff P, Cavalli F, Squiban P, Acres B, et al.;1; Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels. Cancer Gene Ther 2002 Mar;9(3):289-95.
16. Peat N, Gendler SJ, Lalani N, Duhig T, Taylor-Papadimitriou J.;1; Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice. Cancer Res 1992 Apr 1;52(7):1954-60.
17. Guddo F, Giatromanolaki A, Koukourakis MI, Reina C, Vignola AM, Chlouverakis G, et al.;1; MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. J Clin Pathol 1998 Sep;51(9):667-71.
18. Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M, et al.;1; Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther 2011 May;10(5):806-16.
19. Ramlau R, Quoix E, Rolski J, Pless M, Lena H, Levy E, et al.;1; A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol 2008 Jul;3(7):735-44.
20. Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, et al.;1; Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol 2011 Nov;12(12):1125-33.
21. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulieres D, et al.;1; Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005 Sep 20;23(27):6674-81.
22. Wurz GT, Gutierrez AM, Greenberg BE, Vang DP, Griffey SM, Kao CJ, et al.;1; Antitumor effects of L-BLP25 Antigen-Specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model. J Transl Med 2013 Mar 13;11(1):64.
23. Mehta NR, Wurz GT, Burich RA, Greenberg BE, Griffey S, Gutierrez A, et al.;1; LBLP25 vaccine plus letrozole induces a TH1 immune response and has additive antitumor activity in MUC1-expressing mammary tumors in mice. Clin Cancer Res 2012 May 15;18(10):2861-71.
24. Clark WH, Jr., Mastrangelo MJ, Ainsworth AM, Berd D, Bellet RE, Bernardino EA.;1; Current concepts of the biology of human cutaneous malignant melanoma. Adv Cancer Res 1977;24:267-338.
25. Berd D, Mastrangelo MJ.;1; Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+ subset. Cancer Res 1987 Jun 15;47(12):3317-21.
26. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al.;1; Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007 May;56(5):641-8.
27. Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, et al.;1; Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014 Jan;15(1):59-68.
28. Wu YL, Park K, Soo RA, Sun Y, Tyroller K, Wages D, et al.;1; INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer 2011;11:430.
29. Jungbluth AA, Silva WA, Jr., Iversen K, Frosina D, Zaidi B, Coplan K, et al.;1; Expression of cancer-testis (CT) antigens in placenta. Cancer Immun 2007;7:15.
30. Juch H, Blaschitz A, Dohr G, Hutter H.;1; HLA class I expression in the human placenta. Wien Med Wochenschr 2012 May;162(9-10):196-200.
31. Jassim A, Ollier W, Payne A, Biro A, Oliver RT, Festenstein H.;1; Analysis of HLA antigens on germ cells in human semen. Eur J Immunol 1989 Jul;19(7):1215-20.
32. Jungbluth AA, Busam KJ, Kolb D, Iversen K, Coplan K, Chen YT, et al.;1; Expression of MAGE-antigens in normal tissues and cancer. Int J Cancer 2000 Feb 15;85(4):460-5.
33. Kim SH, Lee S, Lee CH, Lee MK, Kim YD, Shin DH, et al.;1; Expression of cancertestis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration. Lung 2009 Nov;187(6):401-11.
34. Marchand M, Punt CJ, Aamdal S, Escudier B, Kruit WH, Keilholz U, et al.;1; Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 2003 Jan;39(1):70-7.
35. Ulloa-Montoya F, Louahed J, Dizier B, Gruselle O, Spiessens B, Lehmann FF, et al.;1; Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol 2013 Jul 1;31(19):2388-95.
36. Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W, et al.;1; Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol 2013 Jul 1;31(19):2396-403.
37. Tyagi P, Mirakhur B.;1; MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 2009 Sep;10(5):371-4.
38. Greenwald RJ, Freeman GJ, Sharpe AH.;1; The B7 family revisited. Annu Rev Immunol 2005;23:515-48.
39. Zou W, Chen L.;1; Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008 Jun;8(6):467-77.
40. Riella LV, Paterson AM, Sharpe AH, Chandraker A.;1; Role of the PD-1 pathway in the immune response. Am J Transplant 2012 Oct;12(10):2575-87.
41. Ramsay AG.;1; Immune checkpoint blockade immunotherapy to activate antitumour T-cell immunity. Br J Haematol 2013 Aug;162(3):313-25.
42. Cameron F, Whiteside G, Perry C.;1; Ipilimumab: first global approval. Drugs 2011 May 28;71(8):1093-104.
43. Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, et al.;1; Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 2013 Jul;24(7):1813-21.
44. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, et al.;1; Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013 Feb 10;31(5):616-22.
45. Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al.;1; Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013 Jan;24(1):75-83.
46. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al.;1; Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012 Jun 10;30(17):2046-54.
47. Ramakrishnan R, Assudani D, Nagaraj S, Hunter T, Cho HI, Antonia S, et al.;1; Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 2010 Apr;120(4):1111-24.
48. Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, et al.;1; Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006 Jan 30;94(2):275-80.
49. PD-1 inhibitors raise survival in NSCLC. Cancer Discov 2014 Jan;4(1):6.
50. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677-704.
51. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012 Jun 28;366(26):2443-54.